David Pace

Summary

Affiliation: University of Oxford
Country: Malta

Publications

  1. pmc Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines
    David Pace
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, UK
    Arch Dis Child 92:909-15. 2007
  2. ncbi request reprint MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection
    David Pace
    Mater Dei Hospital, Department of Paediatrics, Tal Qroqq, Msida, MSD 2090, Malta
    Curr Opin Mol Ther 11:692-706. 2009
  3. doi request reprint Quadrivalent meningococcal conjugate vaccines
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, MSD 2090, Malta
    Vaccine 27:B30-41. 2009
  4. doi request reprint Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, Malta
    Expert Rev Vaccines 8:529-42. 2009
  5. doi request reprint Epidemiology of pathogenic Neisseria meningitidis serogroup B serosubtypes in Malta: implications for introducing PorA based vaccines
    David Pace
    Department of Paediatrics, Mater Dei Hospital, MSD, Malta
    Vaccine 26:5952-6. 2008
  6. doi request reprint A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial
    D Pace
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, UK
    Arch Dis Child 93:963-70. 2008
  7. doi request reprint Quest for the diagnosis. Case 1: a neonatal zoonosis. Neonatal Pasteurella multocida septicaemia
    David Pace
    Department of Paediatrics, St Luke s Hospital, Guardamangia, Malta
    Acta Paediatr 97:250-2. 2008
  8. ncbi request reprint A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants
    David Pace
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, OX3 7LJ, UK
    Pediatr Infect Dis J 26:1057-9. 2007
  9. doi request reprint Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial
    David Pace
    Malta Children s Vaccine Group, Mater Dei Hospital, Tal Qroqq, Msida, MSD 2090, Malta
    BMJ 350:h1554. 2015
  10. doi request reprint Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial
    Matthew D Snape
    Oxford Vaccine Group, University of Oxford, England
    JAMA 299:173-84. 2008

Collaborators

Detail Information

Publications16

  1. pmc Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines
    David Pace
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, UK
    Arch Dis Child 92:909-15. 2007
    ..This article discusses the different glycoconjugate meningococcal vaccines which have been developed and the potential for their use to control disease caused by serogroups A, C, Y and W-135 of Neisseria meningitidis...
  2. ncbi request reprint MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection
    David Pace
    Mater Dei Hospital, Department of Paediatrics, Tal Qroqq, Msida, MSD 2090, Malta
    Curr Opin Mol Ther 11:692-706. 2009
    ....
  3. doi request reprint Quadrivalent meningococcal conjugate vaccines
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, MSD 2090, Malta
    Vaccine 27:B30-41. 2009
    ..This vaccine and others in development offer the potential to broaden population protection against meningococcal disease...
  4. doi request reprint Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, Malta
    Expert Rev Vaccines 8:529-42. 2009
    ..This article discusses this novel quadrivalent vaccine formulation and its potential to control invasive disease caused by N. meningitidis serogroups A, C, Y and W-135...
  5. doi request reprint Epidemiology of pathogenic Neisseria meningitidis serogroup B serosubtypes in Malta: implications for introducing PorA based vaccines
    David Pace
    Department of Paediatrics, Mater Dei Hospital, MSD, Malta
    Vaccine 26:5952-6. 2008
    ....
  6. doi request reprint A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial
    D Pace
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, UK
    Arch Dis Child 93:963-70. 2008
    ....
  7. doi request reprint Quest for the diagnosis. Case 1: a neonatal zoonosis. Neonatal Pasteurella multocida septicaemia
    David Pace
    Department of Paediatrics, St Luke s Hospital, Guardamangia, Malta
    Acta Paediatr 97:250-2. 2008
  8. ncbi request reprint A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants
    David Pace
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, OX3 7LJ, UK
    Pediatr Infect Dis J 26:1057-9. 2007
    ..SBA MenC titers > or =1:8 and anti-PRP concentrations > or =0.15 microg/mL were measured in 99.2% and 100%, respectively, of the infants receiving Hib-MenC-TT...
  9. doi request reprint Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial
    David Pace
    Malta Children s Vaccine Group, Mater Dei Hospital, Tal Qroqq, Msida, MSD 2090, Malta
    BMJ 350:h1554. 2015
    ..To determine whether the immunogenicity of a single dose infant priming schedule of serogroup C meningococcal (MenC) conjugate vaccine is non-inferior to a two dose priming schedule when followed by a booster dose at age 12 months...
  10. doi request reprint Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial
    Matthew D Snape
    Oxford Vaccine Group, University of Oxford, England
    JAMA 299:173-84. 2008
    ..However, the currently licensed vaccine is poorly immunogenic in infancy, when the highest rates of disease are observed...
  11. doi request reprint Meningococcal disease: clinical presentation and sequelae
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, MSD 2090, Malta
    Vaccine 30:B3-9. 2012
    ..The only rational approach to the prevention of meningococcal disease and the associated human suffering is through vaccination...
  12. doi request reprint Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, Malta
    Future Microbiol 5:1629-40. 2010
    ..In Europe, MenACWY-CRM is the first quadrivalent meningococcal glycoconjugate vaccine available to provide broader protection against Neisseria meningitidis serogroups A, C, W-135 and Y...
  13. doi request reprint Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial
    Mildred A Iro
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and NIHR Oxford Biomedical Research Centre, Oxford, UK Electronic address
    Lancet Infect Dis 15:172-80. 2015
    ..We aimed to assess whether this phenomenon also occurs with routine infant vaccines...
  14. pmc Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial
    Ameneh Khatami
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom
    PLoS ONE 9:e101672. 2014
    ..We measured meningococcal serogroup C (MenC)-specific memory B-cell responses in infants by Enzyme-Linked Immunospot (ELISpot) following different MenC conjugate vaccine schedules to investigate the impact of priming on immune memory...
  15. doi request reprint Adequacy of pediatric triage
    Pharrah Debono
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, Malta
    Disaster Med Public Health Prep 6:151-4. 2012
    ..To assess the adequacy of the pediatric triage system in an acute care general hospital...
  16. pmc Manifestations of paediatric Leishmania infantum infections in Malta
    David Pace
    Paediatric Infectious Diseases Clinic, Mater Dei Hospital, Msida, Malta
    Travel Med Infect Dis 9:37-46. 2011
    ..Leishmaniasis should be included in the differential diagnosis of fever and hepatosplenomegaly or chronic cutaneous lesions in children who travel to Malta...